TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34218315
Drug: Weekly guidance
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly guidance on nutrition, physical activity, water intake, and health-promoting behaviors
Study: 33577964
Drug: Ubiquinol (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ubiquinol (300 mg) every 12 h for up to 7 days
Study: 33577964
Drug: Ubiquinol (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ubiquinol (300 mg)
Study: 35986739
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (conventional treatment with oxygen, antibiotics, antispasmodics, antiasthmatic drugs, phlegmolytic drugs, and HFCWO)
Study: 33444396
Drug: FlowOx™ therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: FlowOx™ therapy plus nominal care
Study: 33377925
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate (50 mg/kg loading dose for 15 min, followed by 15 mg·kg-1·h-1 infusion)
Study: 34027993
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (infliximab plus thiopurines)
Study: 35450777
Drug: Non-oral-related practitioners
Normalized name: Tavist Non-Sedating Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-oral-related practitioners
Study: 32011785
Drug: Mindfulness-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based cognitive therapy for 2 months
Study: 35296532
Drug: Certolizumab pegol
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Certolizumab pegol (CZP) 200 mg every 2 weeks
Study: 34311440
Drug: Caffeine mouth
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine mouth rinse (85 mg of caffeine in 25-ml mouth rinse for 5 s every 5 min during exercise)
Study: 32336266
Drug: Drug trial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug trial with presumed superiority of new drug versus equipoise
Study: 32336266
Drug: Drug trial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug trial funded by public sources
Study: 32336266
Drug: Drug trial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug trial with random treatment allocation
Study: 35611396
Drug: Neoadjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant therapy (cisplatin and 5-fluorouracil chemotherapy plus radiotherapy)
Study: 35611396
Drug: Adjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant therapy (cisplatin, 5-fluorouracil, and epirubicin chemotherapy with concurrent extended volume radiotherapy)
Study: 33922493
Drug: Tart Cherry
Normalized name: Tart Cherry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tart Cherry Concentrate (30 mL twice per day for 3 months)
Study: 33922493
Drug: Placebo (isocaloric,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (isocaloric, 30 mL twice per day for 3 months)
Study: 34600487
Drug: ERAS treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ERAS treatment
Study: 33176512
Drug: Lifestyle medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifestyle medicine interventions
Study: 34364386
Drug: Modification of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modification of antihypertensive treatment
Study: 34364386
Drug: Initiation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initiation of antihypertensive treatment
Study: 32844599
Drug: Imidafenacin 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imidafenacin 0.1 mg twice daily
Study: 36900181
Drug: Azacitidine treatment
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine treatment
Study: 33966730
Drug: Silicone gel
Normalized name: SILTREX Silicone Gel-Pad
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicone gel plus Me‐EGF
Study: 33966730
Drug: Silicone gel
Normalized name: SILTREX Silicone Gel-Pad
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicone gel only
Study: 33966730
Drug: No scar
Approvals — FDA: no, EMA: no, PMDA: no
Description: No scar treatment
Study: 36126648
Drug: Hemostatic spray
Normalized name: gas pressurized hemostatic spray device and acces.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemostatic spray
Study: 33556464
Drug: Early AIT
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early AIT with intravenous anakinra (100 mg every 8 hours for 3 days, with tapering) alone
Study: 33556464
Drug: Early AIT
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early AIT with intravenous anakinra plus glucocorticoid (intravenous methylprednisolone, 1-2 mg/kg daily, with tapering)
Study: 33556464
Drug: Late rescue
Normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late rescue treatment (anakinra or tocilizumab)
Study: 35019020
Drug: Chlorhexidine 0.12%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine 0.12% spray
Study: 33051423
Drug: Group 1
Normalized name: Chlamydophila psittaci biogroup 1 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1 (62±2 mL/(kg·min))
Study: 33051423
Drug: Group 2
Normalized name: Chlamydophila psittaci biogroup 2 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2 (72±2 mL/(kg·min))
Study: 33051423
Drug: Group 3
Normalized name: Chlamydophila psittaci biogroup 3 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 3 (82±2 mL/(kg·min))
Study: 35007749
Drug: Operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative treatment with a hook plate
Study: 35007749
Drug: Nonoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoperative treatment (physiotherapy)
Study: 35581660
Drug: Transmucosal diamorphine
Normalized name: Diamorphine
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transmucosal diamorphine (buccal and intranasal routes)
Study: 35686330
Drug: aprocitentan 12.5
Normalized name: aprocitentan 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: aprocitentan 12.5 mg
Study: 33228621
Drug: Higher perceived
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher perceived susceptibility of oral diseases
Study: 33228621
Drug: Higher perceived
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher perceived severity of oral diseases
Study: 33228621
Drug: Flossing weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flossing weekly
Study: 33228621
Drug: Stronger perceived
Normalized name: Strongid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stronger perceived susceptibility, greater severity of oral diseases, less performing of oral health behaviors, higher DMFT score
Study: 33031757
Drug: Cobitolimod 2
Normalized name: Cobitolimod
DrugBank: Cobitolimod (DB14819)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cobitolimod 2 × 250 mg
Study: 33031757
Drug: Cobitolimod 2
Normalized name: Cobitolimod
DrugBank: Cobitolimod (DB14819)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cobitolimod 2 × 31 mg
Study: 33031757
Drug: Cobitolimod 2
Normalized name: Cobitolimod
DrugBank: Cobitolimod (DB14819)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cobitolimod 2 × 125 mg
Study: 33031757
Drug: Cobitolimod 4
Normalized name: Cobitolimod
DrugBank: Cobitolimod (DB14819)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cobitolimod 4 × 125 mg
Study: 33978491
Drug: 50 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g/day dried plum
Study: 33978491
Drug: 100 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 g/day dried plum
Study: 32868360
Drug: One dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of ivermectin-based mass drug administration (MDA)
Study: 32868360
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of ivermectin-based mass drug administration (MDA)
Study: 32868360
Drug: One-dose and
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One-dose and two-dose MDA
Study: 33503305
Drug: Single-agent azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single-agent azacitidine
Study: 32067657
Drug: Combined laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined laser therapy and chiropractic care
Study: 36297102
Drug: Caffeine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (3 mg.kg−1)
Study: 33722384
Drug: Topical ivermectin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ivermectin 1% cream and doxycycline 40-mg modified-release capsules
Study: 33829308
Drug: Oxytocin nasal
Normalized name: oxytocin Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxytocin nasal spray (24 IU intranasal administration)
Study: 35397638
Drug: Intranasal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal insulin (160 IU/1.6 mL)
Study: 35757899
Drug: Hybrid closed-loop
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid closed-loop (HCL) therapy using Medtronic MiniMed™ 670G system
Study: 32226019
Drug: Bright light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright light therapy (10,000 lux)
Study: 32005282
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose hUC-MSCs (2.5 million cells/kg)
Study: 32005282
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose hUC-MSCs (5 million cells/kg)
Study: 32005282
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (traditional supportive treatments alone)
Study: 33064057
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment group (Group 1)
Study: 33438437
Drug: Alirocumab with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab with achieved LDL-C <25 mg/dL
Study: 33438437
Drug: Alirocumab with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab with achieved LDL-C 25 to 50 mg/dL
Study: 33438437
Drug: Alirocumab with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab with achieved LDL-C >50 mg/dL
Study: 32728111
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of orthokeratology (OK) and 0.01% atropine solution
Study: 32728111
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with orthokeratology (OK)
Study: 33472855
Drug: Tocilizumab (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab (single intravenous infusion of 8 mg/kg) plus standard care (n=65)
Study: 32371120
Drug: Micro-training (four
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micro-training (four 15-min strength and four 15-min endurance bouts weekly)
Study: 32371120
Drug: Classical-training (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Classical-training (one 60-min strength and one 60-min endurance training session weekly)
Study: 32371120
Drug: Control-group (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control-group (two 60-min standard military physical training sessions weekly)
Study: 36433884
Drug: Attention Bias
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Attention Bias Modification Treatment (ABMT) as an add-on to regular inpatient treatment, involving two pretreatment training sessions and eight biweekly sessions.
Study: 33618522
Drug: HART-CT (concomitant
Approvals — FDA: no, EMA: no, PMDA: no
Description: HART-CT (concomitant hyperfractionated radiotherapy with chemotherapy)
Study: 34159560
Drug: Colchicine 500
Normalized name: Colchicine 500 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine 500 mcg od
Study: 32880057
Drug: anodal-left PFC
Approvals — FDA: no, EMA: no, PMDA: no
Description: anodal-left PFC tDCS plus placebo medication
Study: 32880057
Drug: escitalopram 10
Normalized name: escitalopram 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: escitalopram 10 mg/day for 3 weeks and 20 mg/day thereafter plus sham tDCS
Study: 32880057
Drug: placebo medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo medication plus sham tDCS
Study: 32243492
Drug: Inclisiran 300
Normalized name: Inclisiran
DrugBank: Inclisiran (DB14901)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Inclisiran 300 mg single dose
Study: 32243492
Drug: Inclisiran 500
Normalized name: Inclisiran
DrugBank: Inclisiran (DB14901)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Inclisiran 500 mg single dose
Study: 32243492
Drug: Inclisiran 100
Normalized name: Inclisiran
DrugBank: Inclisiran (DB14901)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Inclisiran 100 mg double dose
Study: 32243492
Drug: Inclisiran 200
Normalized name: Inclisiran
DrugBank: Inclisiran (DB14901)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Inclisiran 200 mg double dose
Study: 32243492
Drug: Inclisiran 300
Normalized name: Inclisiran
DrugBank: Inclisiran (DB14901)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Inclisiran 300 mg double dose
Study: 32243492
Drug: Placebo single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo single dose
Study: 32243492
Drug: Placebo double
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo double dose
Study: 32243492
Drug: Inclisiran (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inclisiran (all dosing regimens)
Study: 33892624
Drug: Impairments in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Impairments in activities of daily living
Study: 35304647
Drug: Targeted tidal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted tidal volume of 4 ml/kg
Study: 35304647
Drug: Targeted tidal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted tidal volume of 5 ml/kg
Study: 35304647
Drug: Targeted tidal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted tidal volume of 6 ml/kg
Study: 34286472
Drug: Low-dose vitamin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose vitamin D
Study: 33371148
Drug: Active NAE
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active NAE therapy (n=20)
Study: 34979631
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 0.3 mg/kg IV ketamine and 40.0 mg IV parecoxib (group K-P)
Study: 34979631
Drug: 0.3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/kg IV ketamine alone (group K)
Study: 35580635
Drug: Oxygen (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen (10 L per minute by simple, tight‐fitting face mask until delivery)
Study: 33609057
Drug: Flurbiprofen axetil
Normalized name: Flurbiprofen axetil
DrugBank: Flurbiprofen axetil (DB14938)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen axetil injection (test product)
Study: 33609057
Drug: ROPION (reference
Approvals — FDA: no, EMA: no, PMDA: no
Description: ROPION (reference drug)
Study: 32032804
Drug: Active gesture
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active gesture intervention (Visual Action Therapy)
Study: 35063214
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplement (1000 IU + 25 g canola oil daily, n=31)
Study: 35063214
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D fortified oil (placebo tablet + 25 g canola oil fortified with 1000 IU vitamin D daily, n=30)
Study: 35063214
Drug: Control (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (placebo tablet + 25 g canola oil, n=32)
Study: 34882076
Drug: Indapamide retard
Normalized name: Indapamide
DrugBank: Indapamide (DB00808)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indapamide retard 1.5 mg in the morning and valsartan 160 mg in the evening (Group 2)
Study: 34882076
Drug: Indapamide retard
Normalized name: Indapamide
DrugBank: Indapamide (DB00808)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indapamide retard 1.5 mg in the morning and valsartan 80 mg in the morning and evening (Group 3)
Study: 35459688
Drug: Mindfulness-based supportive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based supportive therapy (MBST)
Study: 33107050
Drug: Common treatment
Normalized name: Common carp
DrugBank: Common carp (DB10614)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Common treatment area (owner absent)
Study: 35341011
Drug: Common postoperative
Normalized name: Common carp
DrugBank: Common carp (DB10614)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Common postoperative treatment
Study: 32719254
Drug: Concomitant boost
Normalized name: BOOST
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant boost radiotherapy (CBRT) - 45 Gy/25#/5-weeks and 18 Gy/10# concomitant boost in the last 2-weeks, total dose 63 Gy.
Study: 32719254
Drug: Concomitant boost
Normalized name: BOOST
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant boost with concurrent chemoradiation (CBRT + CCT) - CBRT with cisplatin 75 mg/m2 on day 1, 17, and 34.
Study: 32719254
Drug: Standard fractionation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard fractionation chemoradiation with concomitant chemotherapy (CFRT + CCT) - 64 Gy/32#/6.2 weeks, concurrent with cisplatin 75 mg/m2 on day 1, 22, and 42.
Study: 32371433
Drug: Certolizumab pegol
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Certolizumab pegol (CZP) 400 mg at Weeks 0/2/4, then 200 mg every 2 weeks up to 96 weeks
Study: 35815022
Drug: BEAM intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BEAM intervention (10-week program including weekly videos, activities based on Unified Protocol therapy modules, telehealth group sessions, and online support forum)
Study: 35815022
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as Usual (TAU) control group
Study: 38704973
Drug: Stress management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stress management treatment
Study: 35083557
Drug: Meperidine 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine 12.5 mg (1 mL) added to 0.5% 10 mg (2 mL) of hyperbaric bupivacaine
Study: 35083557
Drug: Sufentanil 5
Normalized name: SUFentanil 50 MCG in 1 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil 5 μg (1 mL) added to 0.5% 10 mg (2 mL) of hyperbaric bupivacaine
Study: 36163869
Drug: Ibrutinib (420
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib (420 mg once daily)
Study: 34043412
Drug: Neoadjuvant capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Neoadjuvant capecitabine and oxaliplatin (CAPOX) followed by concurrent radiation and capecitabine (CAPRT)
Study: 34187081
Drug: Nicotine Replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine Replacement Treatment (NRT)
Study: 34485877
Drug: Sodium selenite
Normalized name: Sodium selenite
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Sodium selenite 100 mcg/day
Study: 36008062
Drug: Web-based psychoeducational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based psychoeducational intervention integrating dialectical behavioural therapy and empowerment approach
Study: 36007135
Drug: 2.5 mL
Normalized name: syringe, disposable, 2.5 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mL sodium bicarbonate in 240 mL isotonic nasal irrigation twice daily for 14 days
Study: 36007135
Drug: 2.5 mL
Normalized name: syringe, disposable, 2.5 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mL povidone-iodine 10% in 240 mL isotonic nasal irrigation twice daily for 14 days
Study: 36007135
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily irrigation (regardless of additive)
Study: 34704970
Drug: Rectal indomethacin
Normalized name: indomethacin Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal indomethacin administered every 8 hours for 6 doses
Study: 34704970
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered every 8 hours for 6 doses
Study: 32458980
Drug: DIM 100
Normalized name: DIM-SA
DrugBank: Succimer (DB00566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DIM 100 mg × 1/day for 1 year
Study: 33287868
Drug: Acupuncture (Jin’s
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture (Jin’s three-needle acupuncture) as adjunctive therapy with methadone maintenance therapy (MMT) for 30 min per session, 18 sessions over 6 weeks (3 per week).
Study: 36155742
Drug: SMS text
Normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMS text messages to parents (twice daily for 1 year)
Study: 33790343
Drug: Upper extremity
Normalized name: lymphedema garments, upper extremity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upper extremity treatment with sonification techniques
Study: 32788051
Drug: Dalfampridine (4-AP,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalfampridine (4-AP, 10 mg BID)
Study: 33407796
Drug: APOSEC (cell-free
Approvals — FDA: no, EMA: no, PMDA: no
Description: APOSEC (cell-free secretome of peripheral blood mononuclear cells) applied topically three times weekly for 4 weeks.
Study: 33407796
Drug: Placebo applied
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo applied topically three times weekly for 4 weeks.
Study: 34187130
Drug: Tualang honey
Normalized name: Honey
DrugBank: Honey (DB14242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tualang honey nasal dressing (2 mL)
Study: 34187130
Drug: Steroid nasal
Normalized name: Corticosteroid nasal preparations for topical use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid nasal dressing (triamcinolone 20 mg/mL, 2 mL)
Study: 32200659
Drug: QL0902 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: QL0902 (50 mg subcutaneous injection)